> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-124/
- Published: 2017-02-26T12:00:00.000Z
- Updated: 2026-09-14T22:08:37.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138073

**Putney ANDA for Mupirocin Ointment Approval Withdrawn**  
*Federal Register* notification of withdrawal: FDA has at the sponsor’s request withdrawn approval of a Putney, Inc. ANDA for mupirocin ointment 2% because the product is no longer manufactured or marketed. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-02-24/pdf/2017-03678.pdf?ref=fdaweb.com).

**20 New Animal Drug Approvals Withdrawn**  
*Federal Register* notification of withdrawal. FDA has withdrawn approval of 18 new animal drug applications and two abbreviated new animal drug applications. The withdrawals involve antimicrobial drugs of importance to human medicine that are administered to food-producing animals in medicated feed, and they are no longer manufactured or marketed. Additionally, the products were identified as being affected by guidance for industry (GFI) #213, “New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions With GFI #209.” To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-02-24/pdf/2017-03595.pdf?ref=fdaweb.com).

**Docket Established for Pediatric Postmarketing Reviews**  
*Federal Register* Notice: FDA has established a public docket to collect comments related to pediatric postmarketing pharmacovigilance and drug utilization reviews of products posted between 9/17/2016 and 2/24/2017 on the agency’s Web site, but will not be presented at a 3/6-7 Pediatric Advisory Committee (PAC) meeting. These reviews are intended to be available for review and comment by members of the PAC, interested parties (such as academic researchers, regulated industries, consortia, and patient groups), and the general public. To view the reviews, click [here](https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/ucm510701.htm?ref=fdaweb.com). To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-02-21/pdf/2017-03365.pdf?ref=fdaweb.com).